S&P 500   3,844.57 (-2.06%)
DOW   31,506.73 (-1.42%)
QQQ   315.04 (-2.80%)
AAPL   122.41 (-2.35%)
MSFT   230.21 (-1.85%)
FB   257.11 (-2.72%)
GOOGL   2,028.23 (-2.67%)
AMZN   3,087.15 (-2.29%)
TSLA   700.16 (-5.64%)
NVDA   533.88 (-7.95%)
BABA   243.05 (-2.91%)
CGC   33.81 (-5.03%)
GE   12.87 (-1.91%)
MU   89.90 (-2.83%)
NIO   48.05 (-7.35%)
AMD   82.96 (-4.58%)
T   28.65 (-2.48%)
F   11.90 (-3.02%)
ACB   11.08 (-4.81%)
DIS   192.87 (-2.35%)
BA   219.95 (-4.09%)
NFLX   537.43 (-2.89%)
BAC   36.14 (-0.66%)
S&P 500   3,844.57 (-2.06%)
DOW   31,506.73 (-1.42%)
QQQ   315.04 (-2.80%)
AAPL   122.41 (-2.35%)
MSFT   230.21 (-1.85%)
FB   257.11 (-2.72%)
GOOGL   2,028.23 (-2.67%)
AMZN   3,087.15 (-2.29%)
TSLA   700.16 (-5.64%)
NVDA   533.88 (-7.95%)
BABA   243.05 (-2.91%)
CGC   33.81 (-5.03%)
GE   12.87 (-1.91%)
MU   89.90 (-2.83%)
NIO   48.05 (-7.35%)
AMD   82.96 (-4.58%)
T   28.65 (-2.48%)
F   11.90 (-3.02%)
ACB   11.08 (-4.81%)
DIS   192.87 (-2.35%)
BA   219.95 (-4.09%)
NFLX   537.43 (-2.89%)
BAC   36.14 (-0.66%)
S&P 500   3,844.57 (-2.06%)
DOW   31,506.73 (-1.42%)
QQQ   315.04 (-2.80%)
AAPL   122.41 (-2.35%)
MSFT   230.21 (-1.85%)
FB   257.11 (-2.72%)
GOOGL   2,028.23 (-2.67%)
AMZN   3,087.15 (-2.29%)
TSLA   700.16 (-5.64%)
NVDA   533.88 (-7.95%)
BABA   243.05 (-2.91%)
CGC   33.81 (-5.03%)
GE   12.87 (-1.91%)
MU   89.90 (-2.83%)
NIO   48.05 (-7.35%)
AMD   82.96 (-4.58%)
T   28.65 (-2.48%)
F   11.90 (-3.02%)
ACB   11.08 (-4.81%)
DIS   192.87 (-2.35%)
BA   219.95 (-4.09%)
NFLX   537.43 (-2.89%)
BAC   36.14 (-0.66%)
S&P 500   3,844.57 (-2.06%)
DOW   31,506.73 (-1.42%)
QQQ   315.04 (-2.80%)
AAPL   122.41 (-2.35%)
MSFT   230.21 (-1.85%)
FB   257.11 (-2.72%)
GOOGL   2,028.23 (-2.67%)
AMZN   3,087.15 (-2.29%)
TSLA   700.16 (-5.64%)
NVDA   533.88 (-7.95%)
BABA   243.05 (-2.91%)
CGC   33.81 (-5.03%)
GE   12.87 (-1.91%)
MU   89.90 (-2.83%)
NIO   48.05 (-7.35%)
AMD   82.96 (-4.58%)
T   28.65 (-2.48%)
F   11.90 (-3.02%)
ACB   11.08 (-4.81%)
DIS   192.87 (-2.35%)
BA   219.95 (-4.09%)
NFLX   537.43 (-2.89%)
BAC   36.14 (-0.66%)
Log in
NASDAQ:ORMP

Oramed Pharmaceuticals Stock Forecast, Price & News

$8.98
-0.39 (-4.16 %)
(As of 02/25/2021 01:37 PM ET)
Add
Compare
Today's Range
$8.61
Now: $8.98▼
$9.79
50-Day Range
$4.22
MA: $7.55▼
$11.33
52-Week Range
$2.40
Now: $8.98▼
$11.71
Volume11,433 shs
Average Volume772,969 shs
Market Capitalization$263.74 million
P/E RatioN/A
Dividend YieldN/A
Beta1.98
Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules or pills for delivery of polypeptides. Its proprietary flagship product is the ORMD-0801, an orally ingestible insulin capsule, which completed phase II clinical trials for the treatment of individuals with diabetes. It is also developing ORMD-0901, an oral glucagon-like peptide-1 capsule that has completed phase I clinical trials for the treatment of type 2 diabetes; and a weight loss treatment in the form of an oral leptin capsule. The company was formerly known as Integrated Security Technologies, Inc. and changed its name to Oramed Pharmaceuticals Inc. in April 2006. Oramed Pharmaceuticals Inc. was founded in 2002 and is based in New York, New York.
Oramed Pharmaceuticals logo

Headlines

Oramed Doses Patients Across Multiple Sites in Phase 3 Oral Insulin Study
January 21, 2021 |  finance.yahoo.com
We're Hopeful That Oramed Pharmaceuticals (NASDAQ:ORMP) Will Use Its Cash Wisely
January 8, 2021 |  finance.yahoo.com
Oramed to Present at H.C. Wainwright BioConnect 2021 Conference
January 7, 2021 |  finance.yahoo.com
Oramed Reports Positive First in Human Data from Oral Leptin Study
December 23, 2020 |  finance.yahoo.com
ORMP: ORMD-0801 in Phase 3 TD2 and NASH Clinical Studies
December 10, 2020 |  finance.yahoo.com
Oramed launches late-stage NASH study with oral insulin
December 4, 2020 |  seekingalpha.com
Is Oramed Pharmaceuticals (ORMP) A Good Stock To Buy Now?
December 4, 2020 |  finance.yahoo.com
Oramed Initiates Phase 2 NASH Trial of Oral Insulin
December 2, 2020 |  finance.yahoo.com
Thinking about buying stock in Hancock Jaffe, Oramed Pharmaceuticals, Tilray, Hexo Corp, or Arbutus Biopharma?
December 1, 2020 |  marketwatch.com
Oramed Pharma screens first patients under its Phase 3 oral insulin trial, shares +8%
November 24, 2020 |  seekingalpha.com
Oramed Initiates Phase 3 Trial of Oral Insulin
November 24, 2020 |  finance.yahoo.com
Oramed Pharmaceuticals Inc. Common Stock (ORMP)
November 19, 2020 |  nasdaq.com
See More Headlines

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:ORMP
Previous Symbol
CUSIPN/A
CIK1176309
Webwww.oramed.com
Phone844-967-2633
EmployeesN/A
Year FoundedN/A

Debt

Debt-to-Equity RatioN/A
Current Ratio8.93
Quick Ratio8.93

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$2.71 million
Price / Sales97.32
Cash FlowN/A
Price / Cash FlowN/A
Book Value$1.40 per share
Price / Book6.41

Profitability

EPS (Most Recent Fiscal Year)($0.56)
Net Income$-11,510,000.00
Net Margins-424.76%
Return on Equity-45.93%
Return on Assets-30.33%

Miscellaneous

Outstanding Shares29,370,000
Market Cap$263.74 million
Next Earnings Date4/5/2021 (Estimated)
OptionableOptionable

MarketRank™

Overall MarketRank™

1.32 out of 5 stars

Medical Sector

680th out of 1,957 stocks

Pharmaceutical Preparations Industry

338th out of 771 stocks

Analyst Opinion: 3.5Community Rank: 3.1Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -
$8.98
-0.39 (-4.16 %)
(As of 02/25/2021 01:37 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive ORMP News and Ratings via Email

Sign-up to receive the latest news and ratings for ORMP and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Oramed Pharmaceuticals (NASDAQ:ORMP) Frequently Asked Questions

Is Oramed Pharmaceuticals a buy right now?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Oramed Pharmaceuticals in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Oramed Pharmaceuticals stock.
View analyst ratings for Oramed Pharmaceuticals or view top-rated stocks.

What stocks does MarketBeat like better than Oramed Pharmaceuticals?

Wall Street analysts have given Oramed Pharmaceuticals a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Oramed Pharmaceuticals wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Oramed Pharmaceuticals?

Oramed Pharmaceuticals saw a increase in short interest during the month of January. As of January 29th, there was short interest totaling 1,250,000 shares, an increase of 54.8% from the January 14th total of 807,700 shares. Based on an average daily volume of 813,500 shares, the days-to-cover ratio is presently 1.5 days. Currently, 5.3% of the company's shares are short sold.
View Oramed Pharmaceuticals' Short Interest.

When is Oramed Pharmaceuticals' next earnings date?

Oramed Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Monday, April 5th 2021.
View our earnings forecast for Oramed Pharmaceuticals.

How were Oramed Pharmaceuticals' earnings last quarter?

Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) issued its earnings results on Wednesday, January, 13th. The biotechnology company reported ($0.23) EPS for the quarter, missing the consensus estimate of ($0.15) by $0.09. The biotechnology company earned $0.67 million during the quarter. Oramed Pharmaceuticals had a negative net margin of 424.76% and a negative trailing twelve-month return on equity of 45.93%.
View Oramed Pharmaceuticals' earnings history.

How has Oramed Pharmaceuticals' stock been impacted by COVID-19 (Coronavirus)?

Oramed Pharmaceuticals' stock was trading at $3.31 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, ORMP shares have increased by 166.2% and is now trading at $8.81.
View which stocks have been most impacted by COVID-19.

What price target have analysts set for ORMP?

4 Wall Street analysts have issued 1 year price targets for Oramed Pharmaceuticals' stock. Their forecasts range from $11.00 to $17.00. On average, they expect Oramed Pharmaceuticals' share price to reach $13.33 in the next twelve months. This suggests a possible upside of 51.3% from the stock's current price.
View analysts' price targets for Oramed Pharmaceuticals or view top-rated stocks among Wall Street analysts.

Who are Oramed Pharmaceuticals' key executives?

Oramed Pharmaceuticals' management team includes the following people:
  • Mr. Nadav Kidron, Pres, CEO & Exec. Director (Age 47, Pay $1.2M)
  • Mr. Avraham Gabay, CFO, Treasurer & Sec. (Age 36, Pay $191.06k)
  • Mr. Joshua Hexter, Chief Operating & Bus. Officer (Age 51, Pay $267.82k)
  • Dr. Miriam Kidron, Chief Scientific Officer & Director (Age 81, Pay $389.19k)
  • Dr. Roy Eldor M.D., Ph.D., Chief Medical Advisor & Member of the Scientific Advisory Board

Who are some of Oramed Pharmaceuticals' key competitors?

Some companies that are related to Oramed Pharmaceuticals include Veru (VERU), Karyopharm Therapeutics (KPTI), Morphic (MORF), ORIC Pharmaceuticals (ORIC), Akero Therapeutics (AKRO), Avid Bioservices (CDMO), ZIOPHARM Oncology (ZIOP), Enanta Pharmaceuticals (ENTA), Epizyme (EPZM), Dynavax Technologies (DVAX), Syndax Pharmaceuticals (SNDX), Humanigen (HGEN), Cara Therapeutics (CARA), Five Prime Therapeutics (FPRX) and Protagonist Therapeutics (PTGX).
View all of ORMP's competitors.

What other stocks do shareholders of Oramed Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Oramed Pharmaceuticals investors own include TransEnterix (TRXC), Compugen (CGEN), Sarepta Therapeutics (SRPT), Zynerba Pharmaceuticals (ZYNE), Inovio Pharmaceuticals (INO), Sorrento Therapeutics (SRNE), DURECT (DRRX), OPKO Health (OPK), Pluristem Therapeutics (PSTI) and Palatin Technologies (PTN).

What is Oramed Pharmaceuticals' stock symbol?

Oramed Pharmaceuticals trades on the NASDAQ under the ticker symbol "ORMP."

Who are Oramed Pharmaceuticals' major shareholders?

Oramed Pharmaceuticals' stock is owned by a number of retail and institutional investors. Top institutional investors include Renaissance Technologies LLC (1.27%), BlackRock Inc. (0.26%), Squarepoint Ops LLC (0.10%), LMR Partners LLP (0.08%), Jane Street Group LLC (0.07%) and LPL Financial LLC (0.05%).
View institutional ownership trends for Oramed Pharmaceuticals.

Which institutional investors are selling Oramed Pharmaceuticals stock?

ORMP stock was sold by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, BlackRock Inc., Jane Street Group LLC, and LMR Partners LLP.
View insider buying and selling activity for Oramed Pharmaceuticals or view top insider-selling stocks.

Which institutional investors are buying Oramed Pharmaceuticals stock?

ORMP stock was bought by a variety of institutional investors in the last quarter, including Squarepoint Ops LLC, LPL Financial LLC, HighTower Advisors LLC, and Oppenheimer & Co. Inc..
View insider buying and selling activity for Oramed Pharmaceuticals or or view top insider-buying stocks.

How do I buy shares of Oramed Pharmaceuticals?

Shares of ORMP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Oramed Pharmaceuticals' stock price today?

One share of ORMP stock can currently be purchased for approximately $8.81.

How much money does Oramed Pharmaceuticals make?

Oramed Pharmaceuticals has a market capitalization of $258.75 million and generates $2.71 million in revenue each year. The biotechnology company earns $-11,510,000.00 in net income (profit) each year or ($0.56) on an earnings per share basis.

What is Oramed Pharmaceuticals' official website?

The official website for Oramed Pharmaceuticals is www.oramed.com.

Where are Oramed Pharmaceuticals' headquarters?

Oramed Pharmaceuticals is headquartered at 1185 AVENUE SUITE 228, NEW YORK NY, 10036.

How can I contact Oramed Pharmaceuticals?

Oramed Pharmaceuticals' mailing address is 1185 AVENUE SUITE 228, NEW YORK NY, 10036. The biotechnology company can be reached via phone at 844-967-2633 or via email at [email protected]


This page was last updated on 2/25/2021 by MarketBeat.com Staff
Receive Analysts' Upgrades and Downgrades Daily

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.